EnteroMedics Spikes Up 20% Following FDA Approval Of Neuroblocking Obesity Device

The U.S. FDA announced Wednesday that it has approved the EnteroMedics Inc ETRM Maestro Rechargeable System for certain obese adults, the first weight-loss treatment device that targets the nerve pathway between the brain and the stomach that controls feelings of hunger and fullness.

The Maestro Rechargeable System, the first FDA-approved obesity device since 2007, is approved to treat patients aged 18 and older who have not been able to lose weight with a weight-loss program, and who have a body mass index of 35 to 45 with at least one other obesity-related condition, such as type 2 diabetes.

“Obesity and its related medical conditions are major public health problems,” said William Maisel, M.D., M.P.H., deputy director for science and chief scientist in the FDA’s Center for Devices and Radiological Health. “Medical devices can help physicians and patients to develop comprehensive obesity treatment plans.”

Shares of EnteroMedics soared on the news and recently traded at $1.44, up 22.03 percent.